iBio and AstralBio Provide Update on Myostatin Program for Obesity

Stock Information for iBio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About iBio Inc.

iBio to Begin Trading on the Nasdaq Stock Exchange
iBio Reports Fiscal Second Quarter 2025 Financial Results
iBio Announces New Investments from Board Members and Officers
iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio
iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio
iBio Strengthens Board with Appointment of Two New Independent Directors
iBio Reports Fiscal First Quarter 2025 Financial Results
iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.